Rimegepant: Effective Migraine Relief for Triptan-Unsuitable Adults

Research Summary

In a study published in the journal Cephalalgia, researchers explored the use of rimegepant, a calcitonin gene-related peptide antagonist, for treating migraines in adults who cannot use triptans due to intolerance, inefficacy, or contraindications. This randomized, double-blind, placebo-controlled phase 4 trial involved 585 participants who received either a 75-mg dose of rimegepant or a placebo. Results demonstrated that rimegepant significantly outperformed the placebo in providing migraine pain relief at 2 hours, with 55.9% of participants experiencing relief compared to 32.7% in the placebo group. The treatment was well-tolerated, with no severe adverse events reported, offering a promising alternative for those unable to use triptans.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.